| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Alfuzosin hydrochloride is a selective and competitive α1-adrenoceptor antagonist for the treatment of symptomatic BPH (benign prostatic hyperplasia)[3]. In the pithed rat, alfuzosin (0.03-0.3 mg kg-1, i.v.) markedly inhibited pressor responses produced by the alpha 1-selective agonist; alfuzosin (1 mg kg-1, i.v.) had minimal effects against responses mediated by stimulation of prejunctional alpha 2-receptors[4]. Moreover, Alfuzosin hydrochloride is an appropriate candidate drug to prepare a gastro-retention controlled release dosage form[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01685658 | Renal Colic A... 展开 >>cute Renal Colic 收起 << | Phase 4 | Suspended(same study already p... 展开 >>ublished) 收起 << | March 2018 | France ... 展开 >> CH d'Alès Alès, France, 30103 CHU de Nîmes - Hôpital Universitaire Carémeau Nîmes Cedex 9, France, 30029 收起 << |
| NCT01323998 | - | Completed | - | - | |
| NCT01332487 | - | Completed | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.35mL 0.47mL 0.23mL |
11.74mL 2.35mL 1.17mL |
23.48mL 4.70mL 2.35mL |
| 参考文献 |
|---|